Annual Report 2005 - Boehringer Ingelheim

More documents

Recommendations

Info

116 Glossary Human Pharmaceuticals Product name Active ingredient Indication actilyse® alteplase Fibrinolytic treatment of acute myocardial infarction, acute massive pulmonary embolism and ischaemic stroke aggrenox® asasantin® persantin® alesion® flurinol® talerc® ASA / dipyridamole extended release antistax® standardized red wine leaf extract AS195® epinastine Antiallergic agent Prevention of stroke following a first stroke or for transient ischaemic attacks As above and adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement Prevention and treatment of symptoms of chronic venous insufficiency – such as painful swollen, heavy or tired legs aptivus® tipranavir Available as capsules for adults – used coadministered with 200 mg of ritonavir, is indicated for combination antiretroviral treatment of HIV1 infected adult patients with evidence of viral replication, who are highly treatmentexperienced or have HIV1 strains resistant to multiple protease inhibitors atrovent® ipratropium bromide Bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema and asthma berotec® dosberotec® fenoterol a) Symptomatic treatment of acute asthma attacks b) Prophylaxis of exercise induced asthma c) Symptomatic treatment of bronchial asthma and other conditions with reversible airway narrowing e.g. chronic obstructive bronchitis. Concomitant antiinflammatory therapy should be considered for patients with bronchial asthma and steroid responsive chronic obstructive pulmonary disease (COPD) bisolvon® bromhexine Mucolytic for the treatment of acute and chronic bronchopulmonary diseases associated with impaired formation and transport of mucus buscopan® buscapina® catapresan® catapres® catapressan® atensina® <strong>Boehringer</strong> <strong>Ingelheim</strong> A n n u A l R e p o R t 2 0 0 5 butylscopolamine Treatment of abdominal discomfort and pain due to intestinal cramps clonidine All forms of high blood pressure, unless caused by phaeochromocytoma
Product name Active ingredient Indication combivent® ipratropium bromide/ salbutamol cymbalta® xeristar® dulcolax® bisacodyl (tablets, suppositories), sodium picosulphate (drops, pearls, tablets) duovent® bronchodual® berodual® flomax® alna® josir® pradif® secotex® urolosin® flomax® cr alna® ocas® pradif® t urolosin® ocas® Treatment of bronchospasms associated with reversible obstructive airways diseases in patients requiring more than one bronchodilator duloxetine Major depressive disorder (MDD), Diabetic peripheral neuropathic pain (DPNP) fenoterol / ipratropium bromide tamsulosin hydrochloride tamsulosin hydrochloride, Oral Controlled Absorption System inflammide® budesonide Bronchial asthma laxoberal® sodium picosulphate (drops, pearls and tablets) lendormin® lendorm® lindormin® sintonal® Laxative for the treatment of constipation Prevention and treatment of symptoms in asthmic and chronic obstructive pulmonary disease (COPD) patients with reversible bronchospasm Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) Laxative for the treatment of constipation brotizolam Shortterm treatment of disorders of initiating and maintaining sleep metalyse® tenecteplase Fibrinolytic treatment of acute myocardial infarction mexitil® mexitilen® micardis® micardisplus® micardis® hct co-micardis® mexiletine Serious symptomatic ventricular tachycardic heart rhythm disturbances telmisartan telmisartan / hydrochlorothiazide Treatment of essential hypertension Glossary 117
Page 1 and 2:
Value through Innovation Annual Rep
Page 3 and 4:
Contents 2 The Shareholders’ Pers
Page 5 and 6:
Value through Innovation Our vision
Page 7 and 8:
of innovative medications. Our expe
Page 9 and 10:
countries since 2000 encourages us
Page 11:
Shareholders’ Committee Dr Heribe
Page 14 and 15:
10 Our commitment We have committed
Page 16 and 17:
1 For our neighbours We are fundame
Page 18 and 19:
1 For our people To achieve our cor
Page 20 and 21:
1 We foster good leadership at all
Page 22 and 23:
1 For our environment In all our ac
Page 24 and 25:
0 Assessments to date show that our
Page 27 and 28:
Our R&D drive Holger Pfister has be
Page 29 and 30:
New data presented at the 10th Euro
Page 31 and 32:
Thanks to new treatments and innova
Page 33 and 34:
Laboratory assistants at our Qualit
Page 35 and 36:
In addition, our discovery efforts
Page 37 and 38:
the age of 65 combined with an agin
Page 39 and 40:
Clinical development and registrati
Page 41 and 42:
increase the planned patient number
Page 43:
Business Development Our Businesses
Page 46 and 47:
“spiriva® has obviously improved
Page 48 and 49:
Prescription Medicines Boehringer I
Page 50 and 51:
Protection around the clock “In t
Page 52 and 53:
Stroke treatment and prevention Str
Page 54 and 55:
0 Serotonin and norepinephrine also
Page 56 and 57:
Rheumatologic diseases Osteoarthrit
Page 58 and 59:
Asia, Australasia, Africa In all ma
Page 60:
Consumer Health Care Let’s talk a
Page 63 and 64:
Gentle and effective dulcolax® for
Page 65 and 66:
health market. With sales of almost
Page 67 and 68:
is critical
Page 69 and 70: at the end of the 1970s with the ma
Page 71 and 72: Moreover, for Boehringer Ingelheim
Page 73 and 74: Pioneering college course in biotec
Page 75 and 76: heartWhen her Labrador Buster fell
Page 77 and 78: According to the American Veterinar
Page 79 and 80: Cattle There were two highly gratif
Page 81 and 82: Group Management Report
Page 83 and 84: and strength of the group. The grea
Page 85 and 86: cymbalta®, the anti-depressive in-
Page 87 and 88: Components of growth in net sales (
Page 89 and 90: Worldwide growth was achieved by th
Page 91 and 92: Liquid assets declined by 12 % comp
Page 93 and 94: Consolidated Financial Statements 2
Page 95 and 96: C. H. Boehringer Sohn Grundstücksv
Page 97 and 98: C. H. Boehringer Sohn, Ingelheim Co
Page 99 and 100: C. H. Boehringer Sohn, Ingelheim St
Page 101 and 102: The following subsidiaries were exe
Page 103 and 104: 2 Accounting and evaluation methods
Page 105 and 106: 3 Notes to the consolidated balance
Page 107 and 108: 3.3 Financial assets (in millions o
Page 109 and 110: Pension provisions Boehringer Ingel
Page 111 and 112: 4 Notes to the consolidated profit
Page 113 and 114: 4.7 Holding income (in millions of
Page 115 and 116: Other mandatory disclosures accordi
Page 117 and 118: Derivative financial instruments at
Page 119: With the following exception, our a
Page 123 and 124: Animal Health Product name Active i
Page 125 and 126: Comparison of Balance Sheets/ Finan
show all

Annual Report 2005 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?